Nutshell Therapeutics

Nutshell Therapeutics is a clinical-stage biotech company specializing in allosteric small molecule drug discovery and development. Founded in 2013, the company has developed the proprietary ALLOSTAR™ platform, which combines artificial intelligence algorithms with biochemistry and biophysics techniques to identify drug candidates for undruggable or challenging protein targets. The company's approach focuses on discovering allosteric sites on proteins and designing molecules that modulate protein function through non-traditional mechanisms, including protein activators, subtype/mutation selective small molecules, protein-protein interaction regulators, and stabilizers of intrinsically disordered proteins. Nutshell operates an integrated R&D platform with both computational and wet lab capabilities, positioning itself as a leader in AI-driven allosteric drug discovery.